Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Boyce Sarah | President and CEO | May 07 '24 | Option Exercise | 1.24 | 28,000 | 34,720 | 140,117 | May 07 09:52 PM | Boyce Sarah | President and CEO | May 07 '24 | Sale | 25.54 | 28,000 | 715,050 | 112,117 | May 07 09:52 PM | LEVIN ARTHUR A | Director | Apr 19 '24 | Option Exercise | 1.24 | 5,000 | 6,200 | 19,830 | Apr 22 05:28 PM | LEVIN ARTHUR A | Director | Apr 19 '24 | Sale | 22.82 | 5,000 | 114,123 | 14,830 | Apr 22 05:28 PM | LEVIN ARTHUR A | Director | Apr 03 '24 | Sale | 27.11 | 20,000 | 542,214 | 253,872 | Apr 03 08:26 PM | Boyce Sarah | President and CEO | Apr 02 '24 | Option Exercise | 1.24 | 28,000 | 34,720 | 140,117 | Apr 03 06:16 PM | Boyce Sarah | President and CEO | Apr 02 '24 | Sale | 26.25 | 28,000 | 734,919 | 112,117 | Apr 03 06:16 PM | LEVIN ARTHUR A | Director | Mar 19 '24 | Option Exercise | 1.24 | 5,000 | 6,200 | 19,830 | Mar 21 04:10 PM | LEVIN ARTHUR A | Director | Mar 19 '24 | Sale | 23.97 | 5,000 | 119,848 | 14,830 | Mar 21 04:10 PM | MacLean Michael F | Chief Financial Officer | Mar 13 '24 | Option Exercise | 8.82 | 40,000 | 352,800 | 84,093 | Mar 15 04:12 PM | MacLean Michael F | Chief Financial Officer | Mar 13 '24 | Sale | 24.52 | 40,000 | 980,760 | 44,093 | Mar 15 04:12 PM | Boyce Sarah | President and CEO | Mar 12 '24 | Option Exercise | 1.24 | 28,000 | 34,720 | 140,117 | Mar 12 05:29 PM | LEVIN ARTHUR A | Director | Mar 12 '24 | Option Exercise | 1.24 | 25,000 | 31,000 | 42,471 | Mar 12 08:41 PM | Boyce Sarah | President and CEO | Mar 12 '24 | Sale | 22.63 | 28,000 | 633,682 | 112,117 | Mar 12 05:29 PM | LEVIN ARTHUR A | Director | Mar 12 '24 | Sale | 22.03 | 27,641 | 609,017 | 14,830 | Mar 12 08:41 PM | Boyce Sarah | President and CEO | Mar 08 '24 | Option Exercise | 1.24 | 84,000 | 104,160 | 196,117 | Mar 12 05:29 PM | Boyce Sarah | President and CEO | Mar 08 '24 | Sale | 21.39 | 84,000 | 1,796,710 | 112,117 | Mar 12 05:29 PM | Boyce Sarah | President and CEO | Mar 01 '24 | Option Exercise | 1.24 | 84,000 | 104,160 | 196,117 | Mar 05 04:53 PM | Boyce Sarah | President and CEO | Mar 01 '24 | Sale | 20.13 | 84,000 | 1,691,306 | 112,117 | Mar 05 04:53 PM | Boyce Sarah | President and CEO | Jan 22 '24 | Sale | 10.13 | 5,092 | 51,582 | 44,008 | Jan 23 03:13 PM | Flanagan W. Michael | CSTO | Jan 22 '24 | Sale | 10.13 | 4,129 | 41,827 | 35,871 | Jan 23 03:12 PM | McCarthy Teresa | Chief Human Resources Officer | Jan 22 '24 | Sale | 10.13 | 2,065 | 20,918 | 17,035 | Jan 23 03:11 PM | LEVIN ARTHUR A | Director | Jan 22 '24 | Sale | 10.13 | 1,859 | 18,832 | 17,471 | Jan 23 03:14 PM | MacLean Michael F | Chief Financial Officer | Jan 22 '24 | Sale | 10.13 | 1,616 | 16,370 | 16,884 | Jan 23 03:11 PM |
|